ArticleAngiogenesis2019
Anti-secretogranin III therapy of oxygen-induced retinopathy with optimal safety.
Article in Angiogenesis, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 29 citations in OpenAlex.
- Age-independent anti-angiogenic therapy for choroidal neovascularization by targeting secretogranin III.GeroScience · 2026Article
- Secretogranin III: a promising therapeutic target for intraocular neovascular lesions.International ophthalmology · 2025Review
- Feasibility of Ex Vivo Ligandomics.Biomolecules · 2025Article
- Suppression of matrigel-induced choroidal neovascularization by AAV delivery of a novel anti-Scg3 antibody.Gene therapy · 2024Article
- Optimal Humanized Scg3-Neutralizing Antibodies for Anti-Angiogenic Therapy of Diabetic Retinopathy.International journal of molecular sciences · 2024Article
- Acrizanib as a Novel Therapeutic Agent for Fundus Neovascularization via Inhibitory Phosphorylation of VEGFR2.Translational vision science & technology · 2024Article
- Anti-Scg3 Gene Therapy to Treat Choroidal Neovascularization in Mice.Biomedicines · 2023Article
- Secretogranin III Selectively Promotes Vascular Leakage in the Deep Vascular Plexus of Diabetic Retinopathy.International journal of molecular sciences · 2023Article
- Systemic Cytokines in Retinopathy of Prematurity.Journal of personalized medicine · 2023Review
- Comparative ligandomics implicates secretogranin III as a disease-restricted angiogenic factor in laser-induced choroidal neovascularization.The FEBS journal · 2022Article
- Neurovascular abnormalities in retinopathy of prematurity and emerging therapies.Journal of molecular medicine (Berlin, Germany) · 2022Review
- Safety and Efficacy of Systemic Anti-Scg3 Therapy to Treat Oxygen-Induced Retinopathy.Frontiers in bioscience (Landmark edition) · 2022Article
- Secretogranin III stringently regulates pathological but not physiological angiogenesis in oxygen-induced retinopathy.Cellular and molecular life sciences : CMLS · 2022Article
- Article
- Selectively targeting disease-restricted secretogranin III to alleviate choroidal neovascularization.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2022Article
- Optimal Efficacy and Safety of Humanized Anti-Scg3 Antibody to Alleviate Oxygen-Induced Retinopathy.International journal of molecular sciences · 2021Article
- Neurovascular Unit: A New Target for Treating Early Stages of Diabetic Retinopathy.Pharmaceutics · 2021Review
- Neurovascular regulation in diabetic retinopathy and emerging therapies.Cellular and molecular life sciences : CMLS · 2021Review
- Concurrent Physiological and Pathological Angiogenesis in Retinopathy of Prematurity and Emerging Therapies.International journal of molecular sciences · 2021Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
Abstract
Retinopathy of prematurity (ROP) with pathological retinal neovascularization is the most common cause of blindness in children. ROP is currently treated with laser therapy or cryotherapy, both of which may adversely affect the peripheral vision with limited efficacy. Owing to the susceptibility of the developing retina and vasculatures to pharmacological intervention, there is currently no approved drug therapy for ROP in preterm infants. Secretogranin III (Scg3) was recently discovered as a highly disease-restricted angiogenic factor, and a Scg3-neutralizing monoclonal antibody (mAb) was reported with high efficacy to alleviate oxygen-induced retinopathy (OIR) in mice, a surrogate model of ROP. Herein we independently investigated the efficacy of anti-Scg3 mAb in OIR mice and characterized its safety in neonatal mice. We developed a new Scg3-neutralizing mAb recognizing a distinct epitope and independently established the therapeutic activity of anti-Scg3 therapy to alleviate OIR-induced pathological retinal neovascularization in mice. Importantly, anti-Scg3 mAb showed no detectable adverse effects on electroretinography and developing retinal vasculature. Furthermore, systemic anti-Scg3 mAb induced no renal tubular injury or abnormality in kidney vessel development and body weight gain of neonatal mice. In contrast, anti-vascular endothelial growth factor drug aflibercept showed significant side effects in neonatal mice. These results suggest that anti-Scg3 mAb may have the safety and efficacy profiles required for ROP therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.